fda warning letter compounded semaglutide september 2025 letters glp-1 Fda Warning Letters Glp-1 Compounded September 2025 There's lots going on this month at FDA Prescription Drug Freight Fraud, June

Sometimes, small adjustments here can restart progress

Ghashghaei N et al

The combination can significantly reduce appetite and caloric intake, which, if not carefully managed, may lead to dehydration, fatigue, or low blood pressure particularly in individuals also taking antihypertensive medications

Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation

Thousands of GLP-1 prescriptions of experience